Prime Medicine, Inc. Common Stock Market Cap ($567.71 Million)
Market Cap & Net Worth: Prime Medicine, Inc. Common Stock (PRME)
Prime Medicine, Inc. Common Stock market cap. Prime Medicine, Inc. Common Stock (NASDAQ:PRME) has a market capitalization of $567.71 Million ($567.71 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11291 globally and #2937 in its home market, demonstrating a 14.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prime Medicine, Inc. Common Stock's stock price $4.97 by its total outstanding shares 181376856 (181.38 Million). Also see Prime Medicine, Inc. Common Stock cash conversion from operations for how efficiently the company converts equity into cash flow.
Prime Medicine, Inc. Common Stock Market Cap History (2022–2026)
Prime Medicine, Inc. Common Stock market cap history from 2022 to 2026. Data shows change from $3.37 Billion to $901.44 Million (-24.36% CAGR). Check current stock price of Prime Medicine, Inc. Common Stock for real-time trading data and today's change.
Index Memberships
Prime Medicine, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #312 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1156 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.03% | #179 of 263 |
Weight: Prime Medicine, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Prime Medicine, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prime Medicine, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PRME net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
135.88x
Prime Medicine, Inc. Common Stock's market cap is 135.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.37 Billion | $5.21 Million | -$121.82 Million | 646.83x | N/A |
| 2024 | $529.62 Million | $2.98 Million | -$195.88 Million | 177.55x | N/A |
| 2025 | $629.38 Million | $4.63 Million | -$201.14 Million | 135.88x | N/A |
Competitor Companies of PRME by Market Capitalization
Companies near Prime Medicine, Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see Prime Medicine, Inc. Common Stock asset portfolio for a full breakdown of the balance sheet.
Key companies related to Prime Medicine, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Prime Medicine, Inc. Common Stock (2022–2026)
Market capitalization of Prime Medicine, Inc. Common Stock from 2022 to today. Between 2022 and today, Prime Medicine, Inc. Common Stock's market cap moved from $3.37 Billion to $ 901.44 Million, with a yearly change of -24.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $901.44 Million | +43.23% |
| 2025 | $629.38 Million | +18.84% |
| 2024 | $529.62 Million | -67.04% |
| 2023 | $1.61 Billion | -52.31% |
| 2022 | $3.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Prime Medicine, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $567.71 Million USD |
| MoneyControl | $567.71 Million USD |
| MarketWatch | $567.71 Million USD |
| marketcap.company | $567.71 Million USD |
| Reuters | $567.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder ca… Read more